Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2018 Jun 13.

Published in final edited form as: Mol Pharm. 2018 Feb 2;15(3):1309–1318. doi: 10.1021/acs.molpharmaceut.7b01114

DXR Scaffold Efficacy against Glioblastoma. a) Kaplan-Meier curves of overall survival comparing survival rates of No Treatment ( , n=5), acetalated dextran blank scaffold (Ace-DEX/blank, , n=5), 10% w/w doxorubicin (DXR) Ace-DEX scaffold (Ace-DEX/10DXR, , n=7), polylactic acid blank scaffold (PLA/blank, , n=6), 10% w/w DXR PLA scaffold (PLA/10DXR, , n=4). Statistical significance by proportional hazard regression model adjusted for tumor size after resection where *p<0.05 with respect to Ace-DEX/blank, ^†p<0.05 and ^††p<0.005 with respect to No Treatment. b) Quantified BLI the day after tumor resection (Day 1). Mice that survived to the end of the study have markers which are colored green. c) BLI images of mice who survived to the end of the study showing the reduction of BLI signal for Ace-DEX/10DXR compared to the increased signal for PLA/10DXR. BLI scale is in radiance (ρ/sec/cm²/sr). d) Kaplan-Meier curves of progression free survival rates comparing survival of No Treatment ( , n=5), Ace-DEX/blank ( , n=5), Ace-DEX/10DXR ( , n=7), PLA/blank ( , n=6), PLA/10DXR ( , n=4). Tumor progression is defined as a five-fold increase in BLI signal. Statistical significance by proportional hazard regression model adjusted for tumor size after resection where **p<0.01 with respect to Ace-DEX/blank, ^††p<0.01 and ^†††p<0.001 with respect to No Treatment. e) Quantified BLI the day after tumor resection (Day 1) Markers indicating representative mice with comparable starting tumor sizes are highlighted blue. f) Quantified BLI of a representative mouse from each treatment group illustrating tumor growth over time (highlighted in blue in e). No Treatment ( ), Ace-DEX/blank ( ), Ace-DEX/10DXR ( ), PLA/blank ( ), PLA/10DXR ( ).

Inline graphic — DXR Scaffold Efficacy against Glioblastoma. a) Kaplan-Meier curves of overall survival comparing survival rates of No Treatment ( , n=5), acetalated dextran blank scaffold (Ace-DEX/blank, , n=5), 10% w/w doxorubicin (DXR) Ace-DEX scaffold (Ace-DEX/10DXR, , n=7), polylactic acid blank scaffold (PLA/blank, , n=6), 10% w/w DXR PLA scaffold (PLA/10DXR, , n=4). Statistical significance by proportional hazard regression model adjusted for tumor size after resection where *p<0.05 with respect to Ace-DEX/blank, ^†p<0.05 and ^††p<0.005 with respect to No Treatment. b) Quantified BLI the day after tumor resection (Day 1). Mice that survived to the end of the study have markers which are colored green. c) BLI images of mice who survived to the end of the study showing the reduction of BLI signal for Ace-DEX/10DXR compared to the increased signal for PLA/10DXR. BLI scale is in radiance (ρ/sec/cm²/sr). d) Kaplan-Meier curves of progression free survival rates comparing survival of No Treatment ( , n=5), Ace-DEX/blank ( , n=5), Ace-DEX/10DXR ( , n=7), PLA/blank ( , n=6), PLA/10DXR ( , n=4). Tumor progression is defined as a five-fold increase in BLI signal. Statistical significance by proportional hazard regression model adjusted for tumor size after resection where **p<0.01 with respect to Ace-DEX/blank, ^††p<0.01 and ^†††p<0.001 with respect to No Treatment. e) Quantified BLI the day after tumor resection (Day 1) Markers indicating representative mice with comparable starting tumor sizes are highlighted blue. f) Quantified BLI of a representative mouse from each treatment group illustrating tumor growth over time (highlighted in blue in e). No Treatment ( ), Ace-DEX/blank ( ), Ace-DEX/10DXR ( ), PLA/blank ( ), PLA/10DXR ( ).